Nadibact

Quick links to important sections

Nadibact

Method of action: Antiacne

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nadibact

Quick Facts

Property Description
Active ingredient Nadifloxacin
Form Cream, Gel
Pharmacological class Fluoroquinolone Antibiotic (Topical)
Common use Resolution of bacterial skin infections
Origin Synthetic

Nadibact is a brand name for a pharmaceutical preparation intended for the topical treatment of bacterial skin conditions. It utilizes the synthetic chemical substance, Nadifloxacin, as its sole active ingredient.

Nadifloxacin: A Targeted Fluoroquinolone Anti-infective

Nadibact contains Nadifloxacin, which is recognized within pharmacological literature as a fluoroquinolone antibiotic, a specialized class of anti-infective agents. The active compound is a synthetic molecule designed for external use on the skin, exerting a powerful bactericidal action against susceptible microorganisms. Nadifloxacin is clinically recognized for its robust action against bacteria involved in dermal conditions, providing a broad-spectrum approach to anti-infective treatment.

By delivering the active agent topically in a cream or gel base, the formulation achieves high local concentrations where they are needed most. This focused approach is preferred in dermatology to minimize systemic exposure.

Composition, Form, and General Purpose

The active ingredient, Nadifloxacin, is consistently formulated for topical application in semi-solid dosage forms, typically available as a cream or a gel base. The general therapeutic purpose of Nadibact is to resolve superficial bacterial skin infections. The mechanism by which the fluoroquinolone works is by inhibiting essential bacterial enzymes, specifically DNA gyrase and topoisomerase IV, thereby preventing normal bacterial DNA synthesis and cell division. This bactericidal effect provides an effective means for the elimination of susceptible bacterial strains and the resolution of the superficial infection.

What side effects are possible with Nadibact?

Possible Side Effects and Safety Information

The safety profile of Nadibact (nadifloxacin topical) is primarily characterized by effects occurring at the site of application, reflecting its use as a topical fluoroquinolone antibiotic. Regulatory authorities classify these events, which are typically confined to the skin and subcutaneous tissue.


Official Adverse Reactions and Frequency

Adverse reactions are classified based on official regulatory data, mainly involving the Skin and subcutaneous tissue disorders system-organ class.

Classification Common Reactions Uncommon Reactions
Application-Site Effects Itching (Pruritus) Burning sensation, Irritation, Erythema (Redness), Dry skin, Contact dermatitis, Pustules

Serious reactions are not typically reported for the topical form. However, because nadifloxacin belongs to the fluoroquinolone class, official labeling mandates inclusion of warnings for serious systemic risks associated with the class, such as tendon rupture and peripheral neuropathy.


Safety Constraints and Special Populations

Official prescribing information includes specific limitations for safe use. The medicine is contraindicated in individuals with a known hypersensitivity to nadifloxacin or any excipients. Contact with the eyes and mucous membranes must be avoided, and application to damaged skin (e.g., cuts or grazes) is restricted.

Regarding specific populations:

  • Pediatrics: Safety and effectiveness have not been adequately established in children younger than 14 years.
  • Pregnancy/Lactation: Use during pregnancy requires caution, and the medicine should not be used during lactation.

Overdose and Emergency Response

The official regulatory information for Nadibact defines overdose primarily through the circumstances of exposure: excessive topical use or accidental oral ingestion.

Documented Overdose Manifestations and Actions

The local risk associated with repeated and excessive topical applications is officially documented to include manifestations such as marked reddishness and discomfort at the application site. Regulatory text states that applying the product excessively will not improve or accelerate therapeutic recovery. The physiological systems explicitly noted as affected in this context are localized skin tissues.

When to Seek Immediate Medical Help

The product is explicitly intended for topical use only and is not for oral administration. Consequently, the primary event requiring urgent medical attention is involuntary oral ingestion. This is the critical scenario that mandates immediate medical assessment.

Official Supportive Measures

In the event of involuntary oral ingestion, official guidance directs that a suitable method of gastric lavage should be considered by a healthcare professional, provided the quantity of nadifloxacin accidentally ingested was not small. The requirement for immediate medical attention and potential supportive intervention reflects the systemic risk associated with this route of exposure, even though specific severe systemic outcomes following ingestion are not explicitly listed in the overdose section.

Therapeutic Uses of Nadibact

What Nadibact Treats: Main Uses and Benefits

Nadibact, which contains the active ingredient nadifloxacin, is primarily used for its role in the topical management of certain skin conditions where bacteria contribute to the symptomatic burden. This medicine is relevant in the topical management of certain bacterial skin infections and a type of acne.

Nadifloxacin is relevant for the management of certain inflammatory forms of acne vulgaris (such as papulopustular acne). It is commonly used to help with the management of superficial bacterial skin infections including impetigo, folliculitis, furunculosis, and secondarily infected wounds or atopic dermatitis.

The compound is applied in addressing the bacterial component associated with these conditions. It plays a role in managing the symptoms related to bacterial activity and supports the patient during episodes of heightened discomfort. In clinical settings that involve acute or unstable symptom patterns, this medicine is relevant for managing symptoms related to inflammatory or irritative states caused by bacteria and assists with maintaining functional stability. It supports general well-being during symptomatic phases.

“This therapy is commonly used in settings marked by temporary physiological imbalance where additional management of discomfort is required.”

Quick Fact: Used for managing Symptoms related to Inflammatory or Irritative States

Regulatory References

  1. Nadifloxacin - FDA Verification Portal

Eligibility and Restrictions for Use

Who Can and Cannot Use Nadibact?

The population eligibility for Nadibact (Nadifloxacin) is defined by regulatory criteria, primarily focusing on hypersensitivity, age, and specific physiological states.


Official Eligibility Constraints

Category Regulatory Status
Absolute Contraindication Contraindicated in patients with known hypersensitivity to Nadifloxacin or any other quinolone antibacterial agent.
Pediatric Use Not recommended for children younger than 14 years; safety and effectiveness are not established in this age group.
Pregnancy/Lactation Pregnancy: Use should only be considered after careful evaluation of expected benefits and risks. Lactation: Use is not recommended; application to the breast area must be avoided.
Organ Function Restrictions for renal or hepatic impairment are not applicable due to the topical route of administration.

Eligibility-Related Restrictions

Use of Nadibact must be avoided on damaged skin (cuts and grazes) and should not be used under occlusive dressings. The medicine is generally advised for use as monotherapy to manage skin conditions.

What should I know about interactions with other medicines?

The official regulatory profile for Nadibact (Nadifloxacin) describes a limited interaction structure defined by its topical use. Due to the very low rate of systemic absorption following application to the skin, pharmacokinetic or exposure-modifying interactions with medicinal products administered via the systemic route are officially classified as very unlikely. This low absorption profile minimizes the regulatory concern for drug-drug interactions involving metabolic pathways or drug transporters.

The documented interactions are localized, characterized as a pharmacodynamic additive effect. Regulatory labels state that co-administration with certain topical product categories may lead to an increase in skin irritation. This restriction applies to the use of peeling agents, astringents, and products containing irritant substances such as aromatic agents and alcohols. These substances are cited in official documentation as capable of exacerbating local adverse effects when used concurrently.

A key regulatory constraint is the mandatory requirement for monotherapy with respect to other topical acne treatments (for example, benzoyl peroxide). This restriction is in place because official data concerning the safety of concomitant use are not available, thereby constraining combined administration. No population-specific interaction considerations are explicitly noted in the regulatory documents.

Mechanism of Action

How Nadibact Works

Nadibact's action is governed by the specialized pharmacodynamics of its active ingredient, Nadifloxacin, which operates primarily through two critical mechanistic domains within the bacterial cell and the surrounding skin tissue.


Direct Disruption of Bacterial Genetic Integrity

This core mechanism involves Nadifloxacin's action as an inhibitor of two essential bacterial enzymes: DNA Gyrase and Topoisomerase IV. By binding to and trapping these enzymes in a complex with the bacterial DNA, the drug prevents them from completing crucial tasks necessary for DNA maintenance and replication. This interference introduces permanent DNA strand breaks, rapidly triggering the bactericidal effect, resulting in the subsequent reduction of the pathogenic bacterial load.


Modulation of Local Tissue Response

Beyond its direct microbe-killing action, Nadifloxacin may engage a secondary mechanistic domain by modulating the host's local inflammatory pathways within the skin. This effect, separate from the antimicrobial activity, influences the activity of local immune cells and the release of pro-inflammatory mediators, altering the local inflammatory cascade.

Dosage and Administration Information

How to Use Nadibact

Nadibact, which contains the active ingredient Nadifloxacin, is administered based strictly on the guidelines for topical anti-infective agents. The usage protocol specifies the route, frequency, and duration of application, as outlined by official product prescribing information.


Administration Protocol

The approved route of administration is topical for external use only. The medicine is consistently formulated as a 1% concentration cream or gel. The standard adult dosing regimen requires applying a thin layer to the entire affected skin area.

Application frequency is standardized as twice daily, typically scheduled once in the morning and again before retiring to bed. Before application, the skin should be thoroughly cleaned and dried. Care must be taken to avoid contact with eyes, lips, and other mucous membranes.


Duration and Restrictions

The typical treatment duration is generally up to 8 weeks, with the maximum course length restricted to 12 weeks if medically acceptable. This topical preparation should not be used under occlusive conditions, such as tight dressings or bandages, as this can affect local concentration and absorption.

Specific guidelines address use in younger populations: the medicine is not advised for children younger than 14 years because safety and effectiveness in this specific pediatric age group have not been sufficiently established in official documentation. These high-level instructions define the standardized approach to administering Nadibact as specified.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the published research and clinical trials that have examined the drug. The information below describes what researchers have investigated and what findings have been reported. Research has included studies that focused on use in pregnant women.


Phase II Trial Findings

Phase II trials typically examine the drug’s performance and further assess its short-term characteristics.

  • One study included findings that participants receiving the drug reported a reduction in symptoms across a range of doses.
  • Research examined the combination therapy and studied its influence on symptom reporting, noting that the study explored possible long-term follow-up.
  • Results indicated a reported lower frequency of flare-ups for a number of participants, though findings varied between individual subjects.

Phase III Trial Findings

Phase III trials examine the drug’s characteristics and monitor adverse events in larger groups of people. A large trial assessed the drug's characteristics related to adverse events and reported on a range of adverse events.

  • Research included studies that compared this compound to other treatments, examining differences in reported patient outcomes.
  • Research has included studies that examined the use of this medication in people with severe X.

Note: This summary describes the findings and focus of studies. It does not constitute medical advice or recommendations regarding treatment suitability.

Key Studies & References Management of skin and soft-tissue infections and acne with topical nadifloxacin: a comprehensive review

Frequently Asked Questions (FAQ)

Common questions about Nadibact (FAQ)


Q: Is it okay to use Nadibact and Benzoyl Peroxide at the same time?

A: Official regulatory constraints specify that Nadibact should be used as a monotherapy for acne, meaning it should not be used at the same time as other topical acne treatments, such as benzoyl peroxide. This restriction is primarily due to a lack of available safety data for combining these products in the official prescribing information.


Q: Can I use other moisturizing creams with Nadibact?

A: Regulatory labeling advises caution when using Nadibact with topical products that may increase skin irritation. Information regarding the co-administration of non-irritating moisturizing creams is not explicitly detailed in the regulatory label. Any change to a topical regimen should be discussed with a healthcare professional.


Q: Is it better to apply Nadibact in the morning or evening?

A: The standard application schedule for Nadibact is twice daily, once in the morning and once before retiring to bed. Regulatory documents do not indicate that one application time offers a greater therapeutic advantage than the other; the timing is generally established for patient convenience.


Q: What is the recommended duration of treatment with Nadibact?

A: According to regulatory guidelines, the duration of treatment is typically up to 8 weeks, with the maximum course length restricted to 12 weeks. The length of time for treatment is typically decided upon consultation with a healthcare professional, based on the specific condition being treated.


Q: What if I swallow a small amount of Nadibact accidentally?

A: Nadibact is strictly for topical use, and contact with the mouth should be avoided. Accidental ingestion should be reported to a healthcare professional for guidance.


Q: Can Nadibact be used for fungal infections?

A: No. Nadibact is a fluoroquinolone antibiotic specifically indicated for the topical treatment of bacterial skin infections. It is not approved or intended for use in treating infections caused by fungi.


Q: Is it normal to feel a slight burning or stinging when applying Nadibact?

A: Application-site burning sensation and irritation are listed as reported adverse reactions in the official regulatory safety profile. If this sensation is experienced as severe, persistent, or worsening, consultation with a healthcare professional is advised.


Q: Can men use Nadibact for folliculitis?

A: Yes, Nadibact is indicated for bacterial skin infections, which includes folliculitis. The regulatory guidelines and prescribing information do not include any restrictions based on gender for its use in treating this condition.


Q: Does Nadibact interact with common facial cleansers or toners?

A: Official labeling advises avoiding co-administration with products containing irritant substances such as alcohols, peeling agents, or astringents, as this may increase skin irritation. Any product containing these types of ingredients should be avoided.


Q: What should I do if I forget a dose of Nadibact?

A: The recommended approach, based on official product information, is to skip the missed dose and return to the normal twice-daily schedule with the next application time. Using a double amount to compensate for a missed application is not recommended.


Q: Does Nadibact only come in cream form?

A: No. The active ingredient, Nadifloxacin, is typically available for topical application in either a 1% concentration cream or a gel formulation, as described in regulatory documentation.


Q: Is there a generic version of Nadibact available?

A: Nadifloxacin is the active ingredient in the brand-name product Nadibact. As a chemical substance, Nadifloxacin may be available under various brand names and as generic versions, depending on the specific country or region.


Q: Why do doctors often prescribe Nadibact for bacterial skin issues?

A: Nadibact is a topical fluoroquinolone antibiotic with a bactericidal mechanism of action. This means it works by inhibiting essential bacterial enzymes needed for DNA replication, making it a targeted anti-infective agent for susceptible bacterial strains that cause skin infections.


Q: Is Nadibact effective against antibiotic-resistant bacteria?

A: Clinical trials described in regulatory documents have examined the activity of Nadifloxacin against certain resistant bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The drug has been noted in studies to have activity against certain resistant bacteria.


Q: How long after opening the tube does Nadibact expire?

A: Official instructions specify a strict stability requirement: the product must be discarded 4 weeks after the tube is first opened. This is the 'use-by' date for the opened product, distinct from the sealed expiration date, and is critical for maintaining effectiveness.


Q: Can I use Nadibact on parts of my body other than my face?

A: Yes, Nadibact is indicated for the topical treatment of bacterial skin infections and should be applied to the entire affected skin area. This includes areas like the chest and back, provided you avoid mucous membranes and broken skin.


Q: Is Nadibact helpful for treating eczema that is infected?

A: Nadibact's regulatory indication covers the treatment of bacterial skin infections. Therefore, it is used for secondarily infected skin conditions, which may include conditions like impetiginized dermatitis or eczema where a bacterial infection is present.


Q: Are allergic reactions to Nadibact common?

A: Official information lists known hypersensitivity to Nadifloxacin or any other quinolone as an absolute contraindication for use. While regulatory labels detail potential adverse events, they typically do not provide a specific frequency for rare but serious allergic reactions.


Q: Can teenagers use Nadibact for severe acne?

A: The safety and effectiveness of Nadibact have not been established in children younger than 14 years. However, for individuals aged 14 and older, the medicine is indicated for bacterial skin infections, including acne vulgaris.


Q: Does using more Nadibact make it work faster?

A: The approved instructions specify applying a thin layer of the cream or gel twice daily. Regulatory information does not indicate that using more than the recommended amount will increase the speed of action or provide greater therapeutic benefit.


Q: How quickly does Nadibact get absorbed into the skin?

A: Regulatory pharmacokinetic studies show that following topical application, the systemic absorption of the active ingredient, Nadifloxacin, through the skin is very low. Plasma concentrations typically reach a steady state after several days of repeated application.


Q: Are there any food or drink restrictions while using Nadibact?

A: Since Nadibact is applied topically and has a very low rate of systemic absorption, there are no documented regulatory concerns for food or drink restrictions. There are also no known pharmacokinetic interactions with medications taken orally.


Q: Why is Nadibact sometimes prescribed for pimples on the chest or back?

A: Nadibact is indicated for the topical treatment of acne vulgaris, which frequently affects areas beyond the face. The official protocol allows for application to any affected skin area where a bacterial skin infection is present.


Q: Has Nadibact been approved by major regulatory bodies globally?

A: The active ingredient, Nadifloxacin, has been approved by regulatory bodies in several countries worldwide, including countries in Asia and Europe, for the treatment of bacterial skin infections.


Q: Can Nadibact help with redness left behind after acne clears?

A: The drug's mechanism of action includes modulating local inflammatory pathways in the skin. This anti-inflammatory effect, separate from its bacterial-killing function, may influence local inflammation and associated symptoms like redness.


Q: What is the success rate of Nadibact in treating mild to moderate acne?

A: Clinical trials described in regulatory documents indicate that participants reported a reduction in symptoms and improvement in lesion counts when treated with Nadifloxacin for mild to moderate acne.


Q: Can Nadibact be used for minor cuts or scrapes to prevent infection?

A: Official prescribing information advises caution and states that the application of Nadibact to damaged skin, such as open cuts or grazes, is restricted or must be avoided.


Q: Can Nadibact make my skin more sensitive to the sun?

A: Yes, as the active ingredient belongs to the fluoroquinolone class of antibiotics, it may cause increased photosensitivity. Regulatory warnings advise that prolonged exposure to sunlight or ultraviolet light should be avoided during the course of treatment.


Q: Do I need a prescription to buy Nadibact?

A: In most major jurisdictions where Nadifloxacin is approved for use, it is classified as a prescription-only medicine (POM). This means it requires authorization from a healthcare provider before it can be purchased or dispensed.

How should Nadibact be stored and disposed of?

The storage and disposal of Nadibact (Nadifloxacin topical) must strictly follow the requirements documented in regulatory labeling to maintain the product's stability and safety.


Official Storage Requirements

Condition Regulatory Rule
Temperature Store below the maximum temperature specified on the label, typically 25, C or 30, C.
Handling The product must not be frozen and must be protected from both light and moisture.
Packaging Keep the original container tightly closed after each use.

Stability and Disposal

Official documents mandate that the product is kept out of the sight and reach of children at all times. Regarding stability, the medicine should be discarded 4 weeks after the tube is first opened. Unused or expired Nadifloxacin must not be disposed of via wastewater or household trash; instead, it must be disposed of according to local pharmaceutical waste regulations, such as authorized take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nadibact found in:

A-Z Index: